Form 4: LIXTE Biotechnology Director Rene Bernards Acquires 5,304 Shares Via Stock Options

Director Rene Bernards acquired 5,304 shares of LIXTE Biotechnology Holdings, Inc. through stock options in lieu of quarterly cash compensation.

Summary

• On September 30, 2024, Rene Bernards, a director of LIXTE Biotechnology Holdings, Inc., acquired 5,304 shares of common stock through the exercise of stock options.
• These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
• The options have an exercise price of $1.30 and vested immediately.
• Bernards also holds options to purchase 10,000 shares with an exercise price of $2.37, expiring on June 30, 2029, and 4,149 shares with an exercise price of $2.37, expiring on June 30, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction. The director taking equity instead of cash is mildly positive.

Positives

• A director taking equity in lieu of cash compensation can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's common for directors to receive stock options as part of their compensation, aligning their interests with those of shareholders.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders, as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, LIXTE Biotechnology, Form 4, beneficial ownership, equity compensation